Microvascular surgery has emerged as an attractive area for recent adv
ances in the field of gene therapy. The present study investigated the
survival of ischemic, experimental skin naps after treatment with the
gene encoding vascular endothelial growth factor (VEGF). In 30 Spragu
e-Dawley rats, anterior abdominal skin flaps supplied by the epigastri
c artery and vein were created. Ten animals were treated with a mixtur
e of liposomes and the cDNA encoding the 121-amino acid isoform of VEG
F. Another 10 animals were treated with control plasmid DNA and liposo
me transfection medium; a third group of 10 animals was given physiolo
gic saline. Each solution was injected directly into the femoral arter
y distal to the origin of the epigastric pedicle supplying the flap. F
our days after injection, the pedicle was ligated and blood flow in th
e flap was approximated using dye fluorescence. Seven days later, the
amount of viable tissue within the flap was measured by planimetry. Af
ter the animals were killed, specimens fi-om both the operated and non
operated sides of the abdomen were harvested for immunohistologic evid
ence of VEGF protein expression. Average dye fluorescence indices of t
he three groups (VEGF cDNA, control plasmid, and saline) 2 hours after
pedicle ligation were 35.9, 23.9, and 53.9 percent, respectively (p <
0.05). Compared with the two control groups, flaps receiving VEGF cDN
A had significantly greater tissue viability at the end of 7 days: 93.
9 versus 28.1 percent for the control plasmid DNA group and 31.9 perce
nt for the saline group (p < 0.05). Immunohistochemical staining docum
ented increased deposition of VEGF protein in flaps that were infused
with the VEGF cDNA versus saline alone (p < 0.05). The results indicat
ed that the survival of ischemic tissues can be enhanced by administra
tion of a cDNA encoding VEGF, a protein known to be important in the p
rocess of angiogenesis and wound healing.